Familial Mediterranean fever (FMF) is a hereditary recurrent fever associated with mutations in the gene MEFV encoding pyrin. It is expressed mainly in neutrophils and macrophages, and modulates the production of the potent pro-inflammatory cytokine interleukin-1b through regulation of nuclear factor-kB and caspase-1. The MEFV gene expression depends on multiple levels of regulation. Sequence variants located in the promoter and at the 3 0 -untranslated region of the gene modulate this expression. Two studies demonstrated decreased mRNA levels in FMF patients compared with healthy subjects, whereas two others found no significant differences. The diverse experimental settings may have resulted in variable quantification of the 15 splice variants that have been identified recently. Some of these isoforms are regulated by nonsense-mediated decay in both cell-and transcript-specific manner, and may be differentially translated in THP1 cells. In addition, pyrin may be cleaved by caspase 1. The full-length pyrin was less abundant than the cleaved fragment in mononuclear cells from FMF patients than in controls, whereas the opposite was observed in granulocytes. Altogether, the regulation of MEFV expression is more complex than anticipated in both physiological and pathological conditions. Its deregulation is likely to alter the inflammasome function and subsequently result in uncontrolled inflammation as seen in FMF.
Introduction
Familial Mediterranean fever (FMF) is a recessively inherited systemic auto-inflammatory disease. Autoinflammatory diseases are an expanding group of innate immunity diseases that have been recently revisited as a continuum, which includes diseases with some features of adaptive immune deregulation. They include hereditary recurrent fevers, pyogenic disorders such as the deficiency of interleukin (IL)-1 receptor and pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA), granulomatous diseases such as Crohn's disease and Blau syndrome. FMF is considered the prototype among the hereditary recurrent fevers as the most frequent and the first whose gene has been identified. FMF patients suffer from recurrent and seemingly unprovoked attacks of fever, often associated with peritonitis, pleuritis, arthritis and localized erysipelas-like erythema. The attacks usually last 12-72 h. 1 The inflammatory reaction is characterized by a massive influx of polymorphonuclear leukocytes into the affected tissues.
The gene responsible for FMF, named MEFV, encodes pyrin 2 (alternatively known as marenostrin, 3 ) a protein of 781 amino-acids ( Figure 1 ). Initial computer analysis of pyrin/marenostrin sequence revealed that this protein contains two putative overlapping nuclear binding motifs and shows high homology with the B30/2 rfp transcription factor family. This observation led to the hypothesis that pyrin was a nuclear transcriptional factor. Later, sequence alignments and secondary structure prediction highlighted that the first 100 N-terminal residues of pyrin constituted a novel protein domain named PYrin Domain (PYD), [4] [5] [6] and revealed that PYD was the fourth member of the death domain fold superfamily. PYD orthologs were also identified in several species such as mouse, cow and zebrafish. The PYD is an N-terminal adapter domain that is found in more than 20 human proteins involved in inflammation and apoptosis, such as NLRP3 (NLR family, PYD containing 3), similar to other death domain foldcontaining proteins (for a review see Kohl et al.
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) Recent studies indicate that pyrin modulates the production of the potent pro-inflammatory cytokine IL-1b probably through two major pathways: (i) the N-terminal fragment of pyrin may regulate nuclear factor (NF)-kB activation through interactions with an adapter protein named apoptosis-associated speck-like protein with a caspase-recruitment domain (ASC) [8] [9] [10] and/or with NFkB-p65, 11 and (ii) pyrin regulates caspase-1/IL-1b activation through its interaction with ASC. 12 Addition-ally, the C-terminal B30.2 domain of pyrin, also known as SPRY, directly interacts with caspase-1 to modulate IL-1b production. 13, 14 This domain, together with the B-Box and coiled-coil domains, constitutes a tripartite motif, which is contained in proteins involved in viral recognition. Thus, pyrin is also known as TRIM20. 15 The MEFV gene contains 10 exons. Nearly 200 sequence variants, almost all single-nucleotide substitutions, have been recorded in Infevers, 16 a database dedicated to auto-inflammatory mutations (http:// fmf.igh.cnrs.fr/ISSAID/infevers/). Only a small number of these variants are unambiguously pathogenic, such as M694V, a severe mutation with a founder effect, and no more than half of the reported MEFV variations are associated with the FMF phenotype. The vast majority of genuine FMF-associated mutations are found in the SPRY domain of the protein. How mutations in the MEFV gene can result in so variable an inflammatory phenotype has been only partially elucidated. 17 Most molecular mechanisms that have been hypothesized suggest an impaired or dysregulated interaction of mutant pyrin protein with its partners, resulting in activation of the NLRP3 inflammasomes. 18 Inflammasomes are cytoplasmic multiprotein complexes essential for the maturation of proinflammatory cytokines IL-1b, IL-18 and IL-33. Several inflammasomes have been described on the basis of their constituent stress-sensing components. In NLRP inflammasomes, ASC works as an adapter molecule that connects the stress-sensing component and pro-caspase-1 through its N-terminal PyD domain and C-terminal CARD domain, respectively (for reviews see Chae et al. 18 and Schroder and Tschopp 19 ). This brings two molecules of procaspase-1 into close proximity, leading to proteolytic activation and the subsequent release of the active catalytic domains, p20 and p10. Active caspase-1, in turn, cleaves the 31-kDa precursor form of IL-1b into its biologically active 17-kDa fragment. Given that ASC also interacts with pyrin through PyD, it is possible that pyrin is somehow involved in several inflammasomes as a modulator, or pyrin itself is a component of an inflammasome. Thus, most studies related to pyrin's function in the innate immune system have been focused on the regulation of the caspase-1 activation and subsequent IL-1b secretion. A growing body of evidence suggests, however, that FMF mutations may also lead to dysregulation in the MEFV expression affecting pyrin level.
The past decade has witnessed the explosion of reviews on auto-inflammatory diseases written by scientists and clinicians from a variety of disciplines. Most of them attempted to correlate clinical features with genotypes in patients with auto-inflammatory diseases, or to dissect the underlying inflammatory pathways. However, there has been no review on the regulation of MEFV gene expression in physiological or pathological conditions. In this manuscript, we review the complex regulation of MEFV expression at the RNA and protein levels, summarize the data obtained from various cell lines along with expression data from FMF patients, and discuss impaired regulation of MEFV expression as a possible mechanism of the disease.
MEFV expression at the mRNA level

Cellular expression
Initial expression studies using northern blot experiments detected MEFV mRNA only in peripheral blood leukocytes (PBLs) and in a colorectal adenocarcinoma cell line, SW480.
2 Specific analysis of leukocyte fractions from bone marrow and PBLs showed that MEFV was highly expressed in neutrophils, and to some extent in eosinophils and monocytes, but not in lymphocytes. 20, 21 MEFV is also expressed in dendritic cells and in fibroblasts from synovium, peritoneum and to a lesser extent from skin. 22 This highly specific cellular expression pattern likely accounts for the predilection of FMF patients to develop inflammation in serosal, synovial and skin tissues.
Transcriptional regulation
Numerous mediators, such as lipopolysaccarides, proinflammatory or anti-inflammatory cytokines, can modulate the mRNA expression of the MEFV gene. However, its expression profile is very much dependent on the cellular sources and experimental conditions (Table 1) important for the conservation of the pyrin structure are precisely those which, when mutated, are associated with a severe form of the disease. 39 The SPRY domain is present in several proteins of the tripartite motif family. This domain may interact with viral components. A full colour version of this figure is available at the Genes and Immunity journal online.
MEFV expression in FMF S Grandemange et al sequence. The promoter exhibits a number of consensus binding sites for known transcription factors, for example, sites common in myeloid specific promoters and sites required for cytokine activation ( Figure 2 ). Papin et al. 23 reported that the MEFV 5 0 -flanking region is necessary for responsiveness to tumor necrosis factor, and that it is dependent on a synergistic activation of C/EBPbeta (factor required for cell responsiveness to tumor necrosis factor) and NFkB-p65 (activating factor acting in synergy with C/EBPbeta). We have characterized the minimal MEFV promoter region between nucleotide residues c-41 and c-286, and identified a region with a putative enhancer extending from c-414 to c-571. 24 Further investigation of the 1000-bp sequence upstream of the initiation codon identified a couple of nucleotide variants that may have a role in regulation of the MEFV expression. The novel c-614C4G variant that was found in a heterozygous state in an FMF patient of Arab descent resulted in a 70% decrease in promoter activity as measured by luciferase reporter experiments. The other promoter variant, c-382C4T found in a nonAshkenazi-Jewish asymptomatic individual induced a 100% increased activity. Using electrophoretic mobility shift assay experiments, we observed specific DNAprotein complexes at both -382 and -614 wild-type regions, indicating that nuclear protein(s) were able to bind to these sequences and perhaps contribute to the regulation of enhancer activity. 24 A separate analysis of 36 Turkish FMF patients without MEFV coding region mutations did not find any variants in the putative MEFV promoter region. 25 However, sequencing of the 3 0 -untranslated region revealed several single-nucleotide polymorphisms within two Alu repeats, which were expressed in the MEFV mRNA. The respective singlenucleotide polymorphisms were clustered into two haplotypes, and the frequency of heterozygote genotypes was significantly higher in the patients without coding region mutations compared with healthy controls. 25 These data suggest a role of the 5 0 -and 3 0 -regulatory sequences in the expression of MEFV and pathogenesis of FMF.
Post-transcriptional regulation MEFV is transcribed into a major full-length transcript of 3.5 kb. The first MEFV splice isoform was described by Papin et al. 26 This variant is generated by in-frame alternative splicing of exon 2 (2D) and expressed in PBLs. Seven more transcript isoforms that introduce various combinations of novel exons 2a and 4a, and a 3 0 extension of exon 8 (8ext) were identified in synovial fibroblasts by Diaz et al. 22 Recently, our group 27 and a Lebanese group 28 detected six more weakly expressed transcripts, with various deletions in exon 2, 3, 4, 7 and 8, or a 5 0 extension of exon 9 (9ext) in PBLs, making the total number of known MEFV transcript isoforms hitherto equal to 15. Most of them, if translated, would MEFV expression in FMF S Grandemange et al conduct to a premature stop codon (Figure 3) . The physiological relevance of these alternatively spliced isoforms is still unclear.
To determine which of the transcripts could potentially be expressed at the protein level, we have examined the effect of nonsense-mediated decay (NMD) inhibition on the expression of the MEFV transcripts in various cells. 27 Alternative splicing and NMD pathways are generally coupled in the post-transcriptional regulation of gene expression (for a review see Neu-Yilik and Kulozik 29 ). Indeed, NMD is a mechanism that controls mRNA quality, prevents translation of unnecessary and aberrant transcripts, for example, mutations generating premature terminal codon, and modulates protein level in a cellspecific manner. The indirect inhibition of NMD by cycloheximide in THP1 cells and neutrophils had no effect on the full-length transcript, but dramatically increased the expression of exon 4a transcripts. The expression of exon 8ext and exon 4a transcripts was increased in monocytes, supporting the role for NMD in regulation of MEFV expression in these cells. Direct inhibition of NMD using small interfering RNA against Upf1, one of the components of the NMD machinery, showed that in THP1 cells, NMD has a role in the regulation of a subset of the MEFV isoforms, including transcripts exon 4a and del234. All together, these results demonstrated that the expression of MEFV is regulated by NMD in both a cell-and a transcript-specific manner. Previous reports suggested that variation in NMD efficiency is associated with numerous genetic disorders and responsiveness to treatment. 30 We hypothesize that individual variations in NMD efficiency for alternatively spliced MEFV transcripts may have a role in FMF pathophysiology and, thereby, may account for part of the phenotypic heterogeneity observed in FMF patients.
The MEFV gene expression in FMF patients and controls has been investigated using both semi-quantitative and quantitative PCR analysis. MEFV mRNA levels were decreased in PBLs of symptom-free French FMF patients of Mediterranean origin compared with controls. 31 This effect correlated with the number and the type of mutations, the lowest mRNA expression being observed in patients homozygous for the most severe FMF-associated mutation, M694V. The second study in a Turkish cohort showed significantly lower mRNA levels in PBLs of asymptomatic FMF patients compared with non-FMF controls, and a further decrease in expression was observed during an acute peritonitis attack. However, the MEFV gene expression did not correlate with the patient's genotypes. Interestingly, MEFV expression was significantly decreased in non-FMF control patients with acute appendicitis during the peri-operative period compared with their asymptomatic states. 32 In a recent study, MEFV gene expression levels were marginally lower in Greek FMF patients compared with healthy subjects. 33 In contrast, a study performed in the USA cohort found a tendency for an increased level of the MEFV expression in 19 asymptomatic FMF patients compared with controls, but this result was not statistically significant. 34 These apparent discrepancies are In synovial fibroblasts transiently transfected with myc-tagged pyrin, the full-length and 2a transcripts are cytoplasmic and the 2D isoform showed a mixed pattern. 22 The native pyrin is nuclear in synovial fibroblasts, neutrophils and dendritic cells, but cytoplasmic in monocytes. 22 Thus, the expression of endogenous pyrin is likely related to the existence of various protein isoforms.
Translational regulation
Reasoning that differential protein expression could be the result of differential mRNA regulation, we recently conducted western blot analyses of endogenous proteins expressed in THP1 cells. 27 Parallel overexpression of various cDNAs in HEK293 cells provided us with the migration pattern of each isoform. We obtained bands compatible with the size of the full-length, 2D8ext and 2a4a products demonstrating that, as expected, at least some of these alternatively spliced MEFV transcripts are translated into protein variants. Moreover, in agreement with the results obtained at the mRNA level, the putative 2D8ext was insensitive to NMD, whereas expression of the putative 2a4a was increased after direct inhibition of NMD. Western blots did not demonstrate a significant difference in pyrin levels between single and double variant patients. However, FMF patients of both types showed higher protein expression, compared with controls and non-FMF patients with active inflammation. 34 Post-translational regulation Pyrin expression was shown to be dependent to at least two post-translational modification processes. Pyrin phosphorylation mediates the binding to 14.3.3 at three serine residues located in exon 2. 36 14.3.3 is thought to have a role in apoptosis. As a result of this interaction, full-length pyrin is retained in the cytoplasm. The lack of interaction with the D2-pyrin isoform results in protein translocation to the nucleus. These data reconcile some observations made in vitro about the different subcellular localization of various isoforms.
Pyrin may also be cleaved by caspase 1 at the residue Asp330, producing an N-terminal fragment that increases ASC-independent NF-kB activation through degradation of I-kappa-B-alpha (IKB-a). 11, 18 The Cterminal-cleaved fragment, where most FMF mutations lie, remains cytoplasmic, whereas the N-terminalcleaved fragment translocates along with p65 to the nucleus. Moreover, the pyrin cleavage is increased in peripheral blood mononuclear cells from FMF patients, whereas full-length pyrin seems to be less expressed in patients. However, the pyrin cleavage appears to be celldependent, and in granulocytes, the full-length pyrin was shown to be more abundant in FMF patients than in controls.
Conclusions
This bibliographical work highlighted that MEFV expression is dependent on cell type and inflammatory status. This is probably accounted for by the multiple levels of regulation that the MEFV gene and its products undergo. At the transcriptional level, MEFV is regulated by numerous factors such as interferon a and NF-kB. At the post-transcriptional level, 15 splicing isoforms have been described so far, some of them being subjected to NMD regulation. At the post-translational level, pyrin can be phosphorylated and cleaved. Quantitative and qualitative differences between controls and FMF patients have been observed at all levels, although some of the available data need to be confirmed. Despite rapidly growing data about the regulation of MEFV, several questions remain to be addressed. Are there quantitative and qualitative variations of these alternative MEFV transcripts in physiological and FMF conditions? What is the effect of pro-and anti-inflammatory cytokines and colchicine, the mainstay treatment of FMF, on the expression of these transcripts? Could the possible existence of several MEFV protein variants explain the controversial results of sub-cellular localization studies?
Altogether, the regulation of MEFV expression is much more complex than initially thought, and it is an important issue, because its deregulation is likely to be one of the mechanisms involved in FMF pathogenesis. Even if the exact role of pyrin in innate immunity is controversial, it probably has a direct and/or indirect crucial role in inflammasome regulation, and any qualitative or quantitative modification of its expression may have a critical consequence in the balance between pro-and anti-inflammatory signaling pathways, which may subsequently result in uncontrolled inflammation.
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